Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

Research output: Contribution to journal › Letter › Research › peer-review

Standard

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. / Jensen, Kristian Hastoft; Persson, Gitte; Bondgaard, Anna Louise; Pøhl, Mette.

In: Acta Oncologica, Vol. 57, No. 8, 03.08.2018, p. 1127-1128.

Research output: Contribution to journal › Letter › Research › peer-review

Harvard

Jensen, KH, Persson, G, Bondgaard, AL & Pøhl, M 2018, 'Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer', Acta Oncologica, vol. 57, no. 8, pp. 1127-1128. https://doi.org/10.1080/0284186X.2018.1433877

APA

Jensen, K. H., Persson, G., Bondgaard, A. L., & Pøhl, M. (2018). Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. Acta Oncologica, 57(8), 1127-1128. https://doi.org/10.1080/0284186X.2018.1433877

Vancouver

Jensen KH, Persson G, Bondgaard AL, Pøhl M. Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. Acta Oncologica. 2018 Aug 3;57(8):1127-1128. https://doi.org/10.1080/0284186X.2018.1433877

Author

Jensen, Kristian Hastoft ; Persson, Gitte ; Bondgaard, Anna Louise ; Pøhl, Mette. / Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer. In: Acta Oncologica. 2018 ; Vol. 57, No. 8. pp. 1127-1128.

Bibtex

@article{1f15afbe57e44247bf34c5593e22f252,
title = "Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer",
abstract = "Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.",
author = "Jensen, {Kristian Hastoft} and Gitte Persson and Bondgaard, {Anna Louise} and Mette P{\o}hl",
year = "2018",
month = aug,
day = "3",
doi = "10.1080/0284186X.2018.1433877",
language = "English",
volume = "57",
pages = "1127--1128",
journal = "Acta Oncologica",
issn = "1100-1704",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer

AU - Jensen, Kristian Hastoft

AU - Persson, Gitte

AU - Bondgaard, Anna Louise

AU - Pøhl, Mette

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.

AB - Pharmaceutical blockade of immune checkpoint inhibitors has become a cornerstone in the treatment of several malignancies. Many patients experience immune-related adverse events [Citation1]. However, treatment-related development or reactivation of infectious disease is rarely reported. Here, we present a patient with advanced non-small cell lung cancer (NSCLC), who developed tuberculosis (TB) following treatment with nivolumab, an anti-PD-1 monoclonal antibody.

U2 - 10.1080/0284186X.2018.1433877

DO - 10.1080/0284186X.2018.1433877

M3 - Letter

C2 - 29384034

AN - SCOPUS:85041368920

VL - 57

SP - 1127

EP - 1128

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1100-1704

IS - 8

ER -

ID: 357371239